Resources from the same session
LBA43 - Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
Presenter: Paul Nathan
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA44 - Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004
Presenter: Ana Maria Arance Fernandez
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA45 - First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
Presenter: Paolo Ascierto
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA46 - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
Presenter: Alexander Eggermont
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1076O - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
Presenter: Jeffrey Weber
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA43, LBA44 and LBA45
Presenter: Bartosz Chmielowski
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: James Larkin
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Webcast
Invited Discussant LBA46 and 1076O
Presenter: Rodabe Amaria
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Slides
Webcast